Association between temozolomide-related hematologic toxicity and health-related quality of life (HRQoL) in patients with newly diagnosed glioblastoma
Clicks: 8
ID: 328298
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
2.1
/100
8 views
7 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #228 of 244 articles by views in journal of neuro-oncology
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 244 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
BACKGROUND: Hematologic toxicity is a major adverse event of temozolomide chemoradiotherapy for newly diagnosed glioblastoma. Although severe hematologic toxicity occurs in approximately 10% of patients, its impact on HRQoL is unknown. This study evaluated the association between temozolomide-related hematologic toxicity and HRQoL in patients with newly diagnosed glioblastoma. MATERIAL AND METHODS: Patients with newly diagnosed glioblastoma treated with temozolomide chemoradiotherapy and available HRQoL data from three clinical trials were included. Primary HRQoL outcomes were physical, social, and role functioning, pain, fatigue, nausea/vomiting, and global health status. Severe hematologic toxicity was defined grade 3-4 neutropenia, lymphopenia, thrombocytopenia, or anemia; febrile neutropenia; or prolonged (>30 days) grade 2 toxicity. Associations between severe hematologic toxicity and HRQoL were evaluated using linear mixed models. Clinical relevance was interpreted as glioma-specific minimally important difference thresholds. RESULTS: Among 1288 patients, 8% experienced severe hematologic toxicity during the concomitant phase, 6% during the maintenance and 1% during both. During the concomitant phase, severe hematologic toxicity was more frequent in females and in patients with MGMT promoter methylation. From baseline to week 6, global health mean scores declined by - 8.52 points in patients with severe toxicity and -4.78 points in those without, with a non-significant difference (p = 0.24). Similar patterns were observed for physical, social, and role functioning. Symptom scales were numerically worse in severe toxicity, but not significantly different. During maintenance phase, differences were minor. CONCLUSION: Severe temozolomide-related hematologic toxicity showed no statistically significant association with impaired HRQoL, suggesting limited impact on patient-reported functioning and symptoms. Possible effects on psychological functioning should be examined further.
| Reference Key |
openalex_W7212068121
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Abigirl Machingura, Johannes Weller, Johan A F Koekkoek, Linda Dirven, Matthias Preusser, Patrick Roth, Roger Stupp, Michael Weller, Madeline Pe, Thierry Gorlia, Martin J B Taphoorn, Emilie Le Rhun, Clemens Seidel, EORTC Brain Tumour Group |
| Journal | journal of neuro-oncology |
| Year | 2026 |
| DOI |
10.1093/neuonc/noag224
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.